Cancer Screening

Cancer Screening

NPC GOLD


A next-generation screening test for early detection of nasopharyngeal cancer before symptoms show.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Nasopharyngeal
Cancer
Blood 3-5 Days

NPC GOLD™ is a cancer screening test for early stage nasopharyngeal cancer (NPC). The test detects a DNA fragment of the Epstein-Barr virus called BamHI-W, even if they are in minute amounts, from circulating tumor DNA in blood. This virus is found in almost all patients with nasopharyngeal cancer. In Asia, nasopharyngeal cancer accounts for more than 80% of all cases in the world, with the highest prevalence in Singapore and Malaysia.

NPC GOLD™ can also be used to monitor post-treatment conditions to see if the patient is responding well to treatment. The technology has been clinically validated in a National Cancer Centre Singapore study. With NPC GOLD™, doctors will be able to detect nasopharyngeal cancer earlier and save lives earlier.

Benefits:

  • Non-invasive. Requires only a single draw of blood
  • Targets multi-copy BamHI-W for higher sensitivity and stability
  • 100% specificity and higher sensitivity than conventional tests

Recommended For:

  • Asians aged 40 and above
  • Healthy individuals with family history of NPC, prolonged exposure to air pollutants and salted fish consumption
  • Patients diagnosed with NPC and undergoing treatment

References:
1. M. Neda, G. Mahshid, M. Abdollah, K. Bahman, S. Hamid et al. Osong Public Health and Research Perspectives: 360-3728
2. K.C.A. Chan, J.K.S. Woo, A. King et al. The New England Journal of Medicine. 2017;377(6):513-522
3. J.H. Vo, et al. Scientific Reports. 6:13 (2016)
4. M.H. Tan, J.H. Vo Patent Cooperation Treaty Application No. PCT/SG2016/050611 (2016)
5. K.C. Chan, et al. 119:1838-44 (2013)

LumiRISK


A multi-cancer blood test that detects gene mutations commonly associated with increased risk of developing hereditary cancers.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Multiple Cancers Blood 2-3 Weeks

LumiRISK™ provides a comprehensive coverage of 26 gene mutations to identify an individual’s risk of developing hereditary cancers in one blood test. Each gene in the panel is known to elevate the risk of developing one or more types of cancer. Hence, by covering a range of genes in one panel, we can provide multi-cancer risk assessment for up to seven types of hereditary cancers.

Cancer risk assessment identifies individuals with a higher than average risk of developing cancer, and who may benefit from additional screening and preventive measures. Having a mutant gene does not indicate a presence of cancer, but it does mean you can do something about it.

Benefits:

  • Actionable recommendations that follow leading medical guidelines to manage patients with positive or negative test results
  • Clear clinical interpretation of tested gene mutations
  • Clinical cancer geneticist at Lucence available for genetic counselling discussion with the ordering physician for optimal diagnosis and management

Recommended For:

  • Healthy individuals with a family history of cancer
  • Anyone who would like to find out more about their risk of developing cancer

 

Gene List
APC ATM BMPR1A BRCA1 BRCA2 BRIP1 CDH1 CDKN2A
CDK4 CHEK2 FH FLCN MLH1 MSH2 MSH6 MUTYH
NBN PALB2 PMS2 PTEN RAD51C RAD51D SMAD4 STK11
TP53 VHL

LumiFOCUS


A blood test that detects gene mutations associated with an increased risk of developing a specific type of hereditary cancer.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Breast, Colon, Kidney,
Ovarian, Pancreatic,
Prostate, Stomach
Cancers
Blood 2-3 Weeks

LumiFOCUS™ is a blood test that detects gene mutations which predisposes a person to a specific type of hereditary cancer. The test covers seven types of hereditary cancers. It identifies individuals with higher than average genetic risks of developing cancer, and who may benefit from additional screening and preventive measures to bring down their cancer risks.

When the same cancer happens in the family, it helps to know if it is hereditary. Cancer occurring to multiple family members could arise from mutant genes being inherited down the family line. For example, if your grandmother and aunt both have breast cancer, knowing the presence of a gene mutation can help prepare other family members for lifestyle adjustments including regular screenings.

Benefits:

  • Actionable recommendations that follow leading medical guidelines to manage patients with positive or negative test results
  • Clear clinical interpretation of tested gene mutations
  • Clinical cancer geneticist at Lucence available for discussion with the ordering physician for optimal diagnosis and management

Recommended For:

  • Healthy individuals with a family history of cancer
  • Anyone who would like to find out more about their risk of developing cancer
Gene List
LumiFOCUS™ Breast & Ovarian BRCA1 BRCA2 CDH1
EPCAM MUTYH PTEN
TP53
LumiFOCUS™ Colon APC EPCAM MLH1
MSH2 MSH6 PMS2
LumiFOCUS™ Kidney FH FLCN PTEN
VHL
LumiFOCUS™ Pancreas ATM APC BRCA1
BRCA2 CDKN2A MLH1
MSH2 MSH6 PALB2
PMS2 STK11
LumiFOCUS™ Prostate ATM BRCA1 BRCA2NBN
CHEK2 HOXB13 G84E MLH1
MSH2 MSH6 PMS2
TP53
LumiFOCUS™ Stomach CDH1 MUTYH

To order our tests, please call or email us. Our customer care team will assist you on the ordering process.



Need Help?